ProPhase Labs, Inc. Contract with Customer, Refund Liability
ProPhase Labs, Inc. (PRPH) had Contract with Customer, Refund Liability of $26.00 thousand as of 2020-09-30, per its 10-Q filed 2020-11-19.
Discontinued › Notes
us-gaap:ContractWithCustomerRefundLiability · last filed 2021-03-31
- 2020-09-30: Contract with Customer, Refund Liability $26.00K.
- 2020-06-30: Contract with Customer, Refund Liability $131.00K.
- 2019-12-31: Contract with Customer, Refund Liability $132.00K.
- 2019-09-30: Contract with Customer, Refund Liability $132.00K.
| Period end | Contract with Customer, Refund Liability |
|---|---|
| 2020-09-30 | $26.00K 10-Q · filed 2020-11-19 |
| 2020-06-30 | $131.00K 10-Q · filed 2020-08-11 |
| 2019-12-31 | $132.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $132.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $138.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | $154.00K 10-Q · filed 2019-05-14 |
| 2018-12-31 | $181.00K 10-K · filed 2020-03-26 |
| 2017-12-31 | $480.00K 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |